Table 1 Risks for endometrial cancer in heterozygotes of each path_MMR gene, 10-year survival, and mortality within 10 years.

Age group	Risk of endometrial cancer diagnosed in the age interval for a heterozygote without cancer at or before entry to the age group				10-year survival	Risk of endometrial cancer diagnosed in the age interval indicated and dying of this within 10 years, for a heterozygote without previous cancer at or before entry to the age group
Age group	path_MLH1	path_MSH2	path_MSH6	path_PMS2	10-year survival	path_MLH1	path_MSH2	path_MSH6	path_PMS2
25 to 40 years	2%	2%	2%	0%	89%	0%	0%	0%	0%
25 to 50 years	15%	18%	13%	0%	89%	2%	2%	1%	0%
25 to 60 years	27%	38%	28%	9%	89%	3%	4%	3%	1%
25 to 70 years	35%	47%	41%	13%	89%	4%	5%	5%	1%
40 to 70 years	34%	45%	40%	13%	89%	4%	5%	4%	1%
50 to 70 years	24%	35%	33%	13%	89%	3%	4%	4%	1%
60 to 70 years	11%	14%	18%	4%	89%	1%	2%	2%	0%
40 to 50 years	13%	16%	11%	0%	89%	1%	2%	1%	0%
50 to 60 years	15%	25%	18%	9%	89%	2%	3%	2%	1%

To the left: the upper four rows indicate risk for endometrial cancer from 25 to 40, 50, 60, or 70 years of age, respectively, if hysterectomy is not undertaken before the ages indicated (i.e., the risk for cancers that could have been prevented by hysterectomy at age 25). The middle three rows indicate the risk for heterozygotes from 40, 50, or 60 years of age, respectively, up to 70 years of age, for cancers that could be prevented by hysterectomy at age 40, 50, or 60 years of age, respectively. The lower two rows indicate the risk for heterozygotes in the age intervals indicated, for cancers that could be prevented by hysterectomy at age 40 or 50, respectively.

Search